SPHK2 and neoplasm: Strikingly, we have also demonstrated that targeting SK2 in GBM cells via re-expression of IC1, or by direct pharmacological SK2 inhibition, resulted in reduced tumor growth in vivo, possibly due, in part, to decreased tumor-associated angiogenesis.